Table 1 aCharacteristics of 20,509 patients diagnosed with early-stage (non-distant metastatic) breast cancer during 1996–2004, according to aspirin use within the first year after diagnosis.

From: Association between low-dose aspirin use and breast cancer recurrence: a Danish nationwide cohort study with up to 23 years of follow-up

  

Aspirin use within 1 year after breast cancer diagnosis

 

Total

Yes

No

 

(n = 20,509)

(n = 850)

(n = 19,659)

Age (years)

 Median (IQR)

58 (51–66)

68 (62–72)

58 (51–65)

Age at primary breast cancer diagnosis (years)

 40–49

4108 (20%)

13 (2%)

4095 (21%)

 50–59

7143 (35%)

133 (16%)

7010 (36%)

 60–69

6349 (31%)

351 (41%)

5998 (31%)

 ≥70

2909 (14%)

353 (42%)

2556 (13%)

Menopausal status at primary diagnosis

 Pre-menopausal

<5500

<30

<5500

 Post-menopausal

15,029 (73%)

825 (97%)

14,204 (72%)

 Missing

<10

<10

<10

Charlson Comorbidity Index Score at primary diagnosis

 0

17,493 (85%)

419 (49%)

17,074 (87%)

 1–2

2738 (13%)

374 (44%)

2364 (12%)

 ≥3

278 (1%)

57 (7%)

221 (1%)

Stage

 I

7804 (38%)

301 (35%)

7503 (38%)

 II

8956 (44%)

393 (46%)

8563 (44%)

 III

<3650

<200

<3500

 Missing

<120

<20

<120

Grade

 I

7425 (36%)

328 (39%)

7097 (36%)

 II

3881 (19%)

148 (17%)

3733 (19%)

 III

3030 (15%)

123 (14%)

2907 (15%)

 Not graded

0 (0%)

0 (0%)

0 (0%)

 Missing

6173 (30.1%)

251 (29.5%)

5922 (30.1%)

Number of positive lymph nodes

 Negative

11,050 (54%)

473 (56%)

10,577 (54%)

 1–3 positive nodes

5960 (29%)

236 (28%)

5724 (29%)

 ≥4 positive nodes

3481 (17%)

141 (17%)

3340 (17%)

 Missing

18 (0.1%)

0 (0%)

18 (0.1%)

Tumour size

 ≤20 mm

12,009 (59%)

451 (53%)

11,558 (59%)

 >20 mm

<8500

<400

<8100

 Missing

<10

<10

<10

ER status

 Negative

4318 (21%)

156 (18%)

4162 (21%)

 Positive

15,379 (75%)

669 (79%)

14,710 (75%)

 Missing

812 (4.0%)

25 (2.9%)

787 (4.0%)

Type of primary surgery

 Mastectomy + RT

4661 (23%)

153 (18%)

4508 (23%)

 Mastectomy

8726 (43%)

466 (55%)

8260 (42%)

 BCS + RT

7122 (35%)

231 (27%)

6891 (35%)

Allocated to adjuvant chemotherapy

 Yes

5616 (27%)

86 (10%)

5530 (28%)

 No

14,893 (73%)

764 (90%)

14,129 (72%)

Allocated to endocrine therapy

 Yes

9785 (48%)

470 (55%)

9315 (47%)

 No

10,724 (52%)

380 (45%)

10,344 (53%)

ACE inhibitors/Angiotensin receptor blockersb

 Yes

1884 (9%)

289 (34%)

1595 (8%)

 No

18,625 (91%)

561 (66%)

18,064 (92%)

Statins

 Yes

736 (4%)

213 (25%)

523 (3%)

 No

19,773 (96%)

637 (75%)

19,136 (97%)

Bisphosphonates

 Yes

187 (1%)

16 (2%)

171 (1%)

 No

20,322 (99%)

834 (98%)

19,488 (99%)

Digoxin

 Yes

297 (1%)

63 (7%)

234 (1%)

 No

20,212 (99%)

787 (93%)

19,425 (99%)

Non-aspirin NSAIDs

 Yes

4981 (24%)

277 (33%)

4704 (24%)

 No

15,528 (76%)

573 (67%)

14,955 (76%)

Metformin

 Yes

212 (1%)

32 (4%)

180 (1%)

 No

20,297 (99%)

818 (96%)

19,479 (99%)

Vitamin K anticoagulants

 Yes

242 (1%)

22 (3%)

220 (1%)

 No

20,267 (99%)

828 (97%)

19,439 (99%)

Hormone replacement therapy

 Yes

9266 (45%)

413 (49%)

8853 (45%)

 No

11,243 (55%)

437 (51%)

10,806 (55%)

  1. ACE angiotensin-converting enzyme, ARB angiotensin receptor blockers, BCS breast-conserving surgery, ER oestrogen receptor, IQR interquartile range, NSAID nonsteroidal anti-inflammatory drugs, RT radiation therapy.
  2. aIn accordance with Danish data protection regulations, cell counts <5 and any cells that would allow back-calculation are reported in aggregate.
  3. bFor all confounding drugs, except hormone replacement therapy, numbers show use in the first year after breast cancer diagnosis. For hormone replacement therapy, numbers show ever use before breast cancer diagnosis.
Back to article page